Candel Therapeutics

Candel Therapeutics, founded in Needham, Massachusetts, is a late clinical stage biopharmaceutical company dedicated to developing oncolytic viral immunotherapies for cancer treatment. The company's core mission is to harness the power of viral immunotherapy to provide innovative and effective cancer treatments. Their product offerings focus on off-the-shelf therapies designed to elicit individualized cancer responses, aiming to combine the best aspects of both approaches in a single treatment. Candel Therapeutics primarily serves the United States market.

Notable affiliated individuals and investors include key figures in the biopharmaceutical industry and venture capital firms specializing in healthcare innovations. Candel Therapeutics has achieved significant milestones in clinical trials, demonstrating promising results in treating various types of cancer. The company's impact lies in its potential to revolutionize cancer therapy by offering more personalized and effective treatment options, contributing to advancements in oncology and improving patient outcomes.